AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36334308
Drug: Low-dose cognitively
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cognitively engaging movement games (20-min)
Trial: 36334308
Drug: High-dose cognitively
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cognitively engaging movement games (40-min)
Trial: 35623869
Drug: l-Carnitine (3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-Carnitine (3000 mg/day) for 7 days
Trial: 33594771
Drug: Concomitant durvalumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant durvalumab during chemo/radiation therapy
Trial: 33594771
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional therapy during chemo/radiation therapy
Trial: 33850272
Drug: Sustained-release isosorbide
RxNorm normalized name: isosorbide Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release isosorbide mononitrate (40–60 mg)
Trial: 32233338
Drug: Liraglutide (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (3.0 mg) plus lifestyle therapy
Trial: 32233338
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus lifestyle therapy
Trial: 34879493
Drug: Lidocaine spray
RxNorm normalized name: lidocaine Mucosal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine spray (10%)
Trial: 32770972
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (loading dose of 20,000 or 40,000 IU daily for the first 11 days, followed by a maintenance dose of 2000 IU daily)
Trial: 33752070
Drug: 40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg ASTA
Trial: 33752070
Drug: 40 and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 and 80 mg/kg ASTA
Trial: 33752070
Drug: 0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg/kg ASTA (Control)
Trial: 32836109
Drug: Treatment (Escitalopram)
RxNorm normalized name: Hongo Killer Treatment
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment (Escitalopram)
Trial: 35521002
Drug: Pharmaceutical service
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical service intervention
Trial: 34987595
Drug: Continuous Acupuncture
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Acupuncture Treatment (CAT) group - 5 times/week for 4 weeks
Trial: 34987595
Drug: Intermittent Acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent Acupuncture Treatment (IAT) group - 3 times/week for 4 weeks
Trial: 33162599
Drug: Etomidate infusion
RxNorm normalized name: Etomidate
DrugBank: Etomidate (DB00292)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etomidate infusion at a rate of 0.07 mg kg‐1 min‐1
Trial: 33162599
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion of 0.7 mg kg‐1 min‐1
Trial: 33743292
Drug: 1.8 g
RxNorm normalized name: Calciquid, 1.8 g/5 mL oral syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 g protein/kg body weight (BW)/d
Trial: 33743292
Drug: 1.2 g
RxNorm normalized name: Humidifier 1.2 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g protein/kg BW/d (standard group)
Trial: 34838305
Drug: NaCl (twice/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl (twice/day application for 5 days by caregiver)
Trial: 34031451
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (assumed increase of 20 nmol/L in 25OHD)
Trial: 32101256
Drug: Lebrikizumab 250
RxNorm normalized name: Lebrikizumab 250 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [EBGLYSS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lebrikizumab 250 mg every 4 weeks
Trial: 39009804
Drug: Lebrikizumab 250
RxNorm normalized name: Lebrikizumab 250 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [EBGLYSS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lebrikizumab 250 mg every 2 weeks
Trial: 32101256
Drug: Lebrikizumab (high-dose)
DrugBank: Lebrikizumab (DB11914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lebrikizumab (high-dose)
Trial: 35188581
Drug: Brolucizumab 6
RxNorm normalized name: BROLUCIZUMAB 6 mg in 0.05 mL INTRAVITREAL INJECTION, SOLUTION [BEOVU]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brolucizumab 6 mg loading (three monthly loading doses)
Trial: 35188581
Drug: Brolucizumab 6
RxNorm normalized name: BROLUCIZUMAB 6 mg in 0.05 mL INTRAVITREAL INJECTION, SOLUTION [BEOVU]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brolucizumab 6 mg non-loading (one initial injection)
Trial: 32861442
Drug: G-TL medium
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-TL medium
Trial: 35227250
Drug: Cell-free and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cell-free and concentrated ascites reinfusion therapy (CART)
Trial: 35373003
Drug: TAKE (taking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAKE (taking BP medications as prescribed)
Trial: 35373003
Drug: HOLD (holding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HOLD (holding BP medications dosed more than once daily)
Trial: 32393654
Drug: Intensive atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive atorvastatin (IA) with bone marrow mononuclear cells (MNCs)
Trial: 32393654
Drug: Regular atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular atorvastatin (RA) with bone marrow mononuclear cells (MNCs)
Trial: 32393654
Drug: Intensive atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive atorvastatin (IA) with placebo
Trial: 32075667
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tDCS and attention to the APB muscle
Trial: 32227161
Drug: No cream
RxNorm normalized name: Oil, Multi Ingredient Topical application Oil [AVEENO CREAMY MOISTURIZING OIL]
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No cream
Trial: 35134768
Drug: Passive suspension
RxNorm normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive suspension system 'Levitas' (Technomex, Poland)
Trial: 34426552
Drug: Multicomponent training
RxNorm normalized name: meningococcus B, multicomponent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent training program (daily activities, dancing, gardening, sports/games) twice weekly for 3 months
Trial: 33769656
Drug: Henagliflozin 10
RxNorm normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Henagliflozin 10 mg
Trial: 33769656
Drug: Henagliflozin 5
RxNorm normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Henagliflozin 5 mg and 10 mg
Trial: 35972485
Drug: Remote Ischemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote Ischemic Conditioning (RIC) for 10 to 14 days as an adjunct to guideline-based treatment (n=922)
Trial: 35972485
Drug: Guideline-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-based treatment alone (Control group, n=971)
Trial: 35972485
Drug: Guideline-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-based treatment alone (Control group)
Trial: 34146045
Drug: Anti-VEGF therapy
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-VEGF therapy with SHRM
Trial: 34709526
Drug: Pills
RxNorm normalized name: Lax-Pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pills
Trial: 34164944
Drug: Belimumab 10
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Belimumab 10 mg/kg IV plus standard therapy
Trial: 33977619
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of medications during pregnancy (multivitamins, analgesics, folic acid)
Trial: 33977619
Drug: Attitudes towards
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Attitudes towards medication use during pregnancy
Trial: 33977619
Drug: Association between
RxNorm normalized name: HEPATITIS ASSOCIATED ANTIBODY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Association between nationality and occupation with attitudes about medications
Trial: 33250271
Drug: Patients treated
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients treated with radiotherapy ± chemotherapy
Trial: 32567372
Drug: Placebo granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo granules combined with vitamin E ointment (Control)
Trial: 616857406
Drug: Mobile application
RxNorm normalized name: Mahana IBS CBT Mobile Application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile application social support program via Line, twice per week for 4 weeks after childbirth
Trial: 32738837
Drug: IV levonadifloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV levonadifloxacin 800 mg
Trial: 32738837
Drug: Oral levonadifloxacin
RxNorm normalized name: levofloxacin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral levonadifloxacin 1000 mg
Trial: 34475155
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg secukinumab (pharmacological control group)
Trial: 34475155
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg secukinumab (75% dose reduction)
Trial: 34475155
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg secukinumab + novel tasting drink (group 3)
Trial: 32242820
Drug: Smartphone-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone-based cognitive behavior therapy (CBT) TBHC intervention for pain self-management, 8 weeks, daily or every other day interaction
Trial: 35263650
Drug: Medication abortions
RxNorm normalized name: ALCOHOL 82 mL in 100 mL TOPICAL LIQUID [Bortons Ethyl Rubbing Alcohol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication abortions
Trial: 33563104
Drug: Carbamazepine (CBZ)
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine (CBZ) 400 mg two times daily
Trial: 35263688
Drug: Nutritional therapy
RxNorm normalized name: nutritional therapy for GSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional therapy according to an algorithm based on individualized nutritional requirements
Trial: 32845782
Drug: Tetravalent Influenza
RxNorm normalized name: INFLUENZA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent Influenza Vaccine (TetIV)
Trial: 32845782
Drug: Trivalent Influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent Influenza Vaccine (TriIV)
Trial: 32621903
Drug: Endoscopic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic and minimally invasive surgical therapies for GERD
Trial: 35910816
Drug: Paracervical block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracervical block (4 ml of lidocaine at 4 and 8 o’clock positions)
Trial: 35910816
Drug: Conscious sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conscious sedation (30 mg pentazocine and 10 mg diazepam)
Trial: 36802321
Drug: Evolocumab 420
RxNorm normalized name: evolocumab 420 in 3.5 ML Cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab 420 mg monthly (QM)
Trial: 34187382
Drug: 60 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/kg/day vitamin C as a continuous infusion for 96 hours
Trial: 33783553
Drug: Vitamin K1
RxNorm normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K1 (2.5 mg)
Trial: 34558214
Drug: Intraoperative amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative amino acid (AA) infusion
Trial: 36370961
Drug: Turmeric/piperine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turmeric/piperine (3 g turmeric + 2 mg piperine/day)
Trial: 36370961
Drug: Turmeric (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turmeric (3 g/day)
Trial: 33197609
Drug: 12-month online
RxNorm normalized name: moth bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month online behavioral lifestyle intervention (BLI) with adjunct components
Trial: 34671099
Drug: 0.2 ml
RxNorm normalized name: isopropyl alcohol 0.2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 ml 24% oral sucrose
Trial: 34671099
Drug: 0.2 ml
RxNorm normalized name: isopropyl alcohol 0.2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 ml 30% oral dextrose
Trial: 34605040
Drug: Progressive muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive muscle relaxation and laughter therapy for 40 minutes per session for 3-4 sessions
Trial: 35208555
Drug: Arthrocen 300
RxNorm normalized name: AVOCADO OIL UNSAPONIFIABLES 100 mg / SOYBEAN 200 mg ORAL CAPSULE [ARTHROCEN 300 mg]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthrocen 300 mg/day
Trial: 32204554
Drug: Migratens® Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Migratens® Group (nutraceutical treatment with coenzyme Q10, vitamin D, alpha‐lipoic acid, magnesium, and tryptophan)
Trial: 32204554
Drug: Acupuncture Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture Group (acupuncture treatment according to traditional Chinese medicine principles)
Trial: 36134849
Drug: Surgical Assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical Assessment Tool (SAT) administered at remote hospitals
Trial: 33562729
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g of specific collagen peptides (CP‐G)
Trial: 33562729
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (P‐G)
Trial: 35542991
Drug: Aducanumab high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aducanumab high dose (10 mg/kg target dose)
Trial: 35542991
Drug: Aducanumab low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aducanumab low dose (3 or 6 mg/kg target dose)
Trial: 32785036
Drug: Phytosterol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytosterol (2 g of free‐phytosterols nanoparticles daily for six months)
Trial: 34542900
Drug: Nomogram integrating
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nomogram integrating tumor extension, surgery type, radiotherapy, and chemotherapy
Trial: 33418053
Drug: Subcutaneous allergy
RxNorm normalized name: Callergy Clear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous allergy immunotherapy (3-year course)
Trial: 33441350
Drug: D-mannose powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-mannose powder daily for 6 months
Trial: 33441350
Drug: Placebo powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo powder daily for 6 months
Trial: 35953331
Drug: FRIL (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FRIL (20 μg)
Trial: 35953331
Drug: CTB-ACE2 (0.925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTB-ACE2 (0.925 μg)
Trial: 34256319
Drug: Dose-escalated intensity-modulated
RxNorm normalized name: California intense cedar pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-escalated intensity-modulated radiotherapy (DE-IMRT)
Trial: 34256319
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose intensity-modulated radiotherapy (ST-IMRT)
Trial: 34002559
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment and swallowing function rehabilitation training (Control)
Trial: 33308810
Drug: High-velocity, low-load
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-velocity, low-load resistance exercise once weekly (HVLL1)
Trial: 33308810
Drug: Low-velocity, high-load
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-velocity, high-load resistance exercise once weekly (LVHL1)
Trial: 33308810
Drug: High-velocity, low-load
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-velocity, low-load resistance exercise twice weekly (HVLL2)
Trial: 33308810
Drug: Low-velocity, high-load
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-velocity, high-load resistance exercise twice weekly (LVHL2)
Trial: 35639792
Drug: High-dose cholecalciferol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cholecalciferol (400,000 IU)
Trial: 35639792
Drug: Standard-dose cholecalciferol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose cholecalciferol (50,000 IU)
Trial: 34108081
Drug: Aminoglycosides administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminoglycosides administered in a predialysis schedule
Trial: 34108081
Drug: Aminoglycosides administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminoglycosides administered in a postdialysis schedule
Trial: 33225600
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of pain management 'other' than analgesia
Trial: 33225600
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of oral analgesia
Trial: 33225600
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 'any' analgesia
Trial: 32949500
Drug: Intravesical Pyo
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical Pyo bacteriophage (Pyophage; 20 mL)
Trial: 32949500
Drug: Intravesical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical placebo solution (20 mL)
Trial: 32949500
Drug: Systemically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemically applied antibiotics
Trial: 35803754
Drug: Bilateral single‐injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral single‐injection erector spinae plane block (ESPB) with ropivacaine 0.5%, 15 ml on each side
Trial: 35803754
Drug: Bilateral single‐injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral single‐injection erector spinae plane block (ESPB)
Trial: 35803754
Drug: Patient‐controlled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient‐controlled intravenous analgesia
Trial: 33966019
Drug: Balanced colloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced colloid (6% hydroxyethyl starch 130/0.4 in an isotonic solution)
Trial: 32969548
Drug: Adjuvant radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant radiotherapy (aRT) administered on the tumour bed and pelvis within 6 months of RP.
Trial: 32697031
Drug: Brief cognitive-behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief cognitive-behavioural therapy (CBT-T)
Trial: 32697031
Drug: Standard cognitive-behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cognitive-behavioural therapy (20 sessions)
Trial: 32826769
Drug: Netarsudil 0.02%
RxNorm normalized name: NETARSUDIL 0.02% OPH SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netarsudil 0.02% once-daily
Trial: 33389912
Drug: L-PRF application
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-PRF application in extraction socket
Trial: 34915492
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment arms (with and without Docetaxel)
Trial: 33591006
Drug: EA‐230 (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EA‐230 (90 mg/kg/hr)
Trial: 34779583
Drug: LYT‐100 (deupirfenidone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LYT‐100 (deupirfenidone) 100 mg twice daily
Trial: 34779583
Drug: LYT‐100 (deupirfenidone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LYT‐100 (deupirfenidone) 250 mg twice daily
Trial: 34779583
Drug: LYT‐100 (deupirfenidone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LYT‐100 (deupirfenidone) 500 mg twice daily
Trial: 34779583
Drug: LYT‐100 (deupirfenidone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LYT‐100 (deupirfenidone) 750 mg twice daily
Trial: 34779583
Drug: LYT‐100 (deupirfenidone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LYT‐100 (deupirfenidone) 1000 mg twice daily
Trial: 34779583
Drug: LYT‐100 (deupirfenidone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LYT‐100 (deupirfenidone) 500 mg single dose (fed condition)
Trial: 34779583
Drug: LYT‐100 (deupirfenidone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LYT‐100 (deupirfenidone) 500 mg single dose (fasting condition)
Trial: 34779583
Drug: LYT‐100 (deupirfenidone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LYT‐100 (deupirfenidone) up to 1000 mg twice daily
Trial: 32193992
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with a specific intervention (not specified)